Trial Profile
Phase I/II Clinical Study of TAS0313 in Patients with Solid Tumor
Status:
Suspended
Phase of Trial:
Phase I/II
Latest Information Update: 11 Oct 2022
Price :
$35
*
At a glance
- Drugs TAS-0313 (Primary) ; Pembrolizumab
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Carcinoma; Duodenal cancer; Gallbladder cancer; Giant cell tumours; Glioblastoma; Gliosarcoma; Haemangioendothelioma; Lung cancer; Mesothelioma; Mouth neoplasm; Neuroendocrine carcinoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 01 Nov 2022 Results from Phase 2 part evaluated the efficacy and safety of TAS0313 in patients with GBM, published in the Cancer Immunology Immunotherapy
- 11 Oct 2022 Status changed from recruiting to suspended, as per JapicCTI record
- 08 Jun 2021 Results of an analysis assessing the efficacy of TAS0313 in combined with Pembrolizumab for locally advanced or metastatic Urothelial carcinoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology